A study, called ‘Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing’, has examined how often the results of genetic testing for cancer risk are later reclassified. To read about…
An enormous anonymous donation of more than $18 million has been given to the BC Cancer Foundation to fund cutting-edge treatments. The news was announced in an article by the…
According to a story from crainsnewyork.com, the biotechnology company Gotham Therapeutics has received financing to the tune of $54 million so that it can begin developing drugs to treat rare…
What can you do with half an hour? That’s the question that a new Canadian program asks. An online program called #30MinutesThatMatter gives Canadian patients an opportunity to share how…
The United States Food and Drug Administration has granted the drug Lynparza® (olaparib) Orphan Drug Designation for the treatment of pancreatic cancer. Lynparza is used in the US to treat…
According to a story from BioSpace, AstraZeneca and Merck released a joint announcement recently stating that the US Food and Drug Administration (FDA) has granted Orphan Drug designation to olaparib…
A new study has found that 80 percent of people who have an identifiable genetic risk for cancer due to a mutated BRCA1/2 gene don’t know they're at risk. The…
According to a report by the Stamford Advocate, The Salem Health Cancer Institute recently launched a genetic program to help improve cancer treatment. Salem Health Hospitals and Clinics report that…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
